The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Hahn Mark W since 2018.
This trader's CIK number is 1408502.
At the time of last reporting, Hahn Mark W was the Chief Financial Officer of Verona Pharma Plc. (stock ticker symbol VRNA).
Also see all insider trading activities at Verona Pharma Plc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | VRNA | 0 | $0 | 1,686,280 | $17,162,964 | 914,720 | $0 |
| 2024 | VRNA | 0 | $0 | 2,797,600 | $12,043,643 | 0 | $0 |
| 2023 | VRNA | 0 | $0 | 1,324,232 | $3,398,714 | 0 | $0 |
| 2022 | VRNA | 0 | $0 | 636,096 | $1,073,296 | 0 | $0 |
| 2021 | VRNA | 0 | $0 | 57,976 | $54,376 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | DOVA | 0 | $0 | 2,320 | $43,592 | 0 | $0 |
| 2018 | DOVA | 2,500 | $15,700 | 0 | $0 | 0 | $0 |
2. Dova Pharmaceuticals Inc. (DOVA)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-01 | VRNA | Option Ex | 255,696 | .00 | 0 |
| 2025-08-01 | VRNA | Sale | 208,912 | 13.14 | 2,745,939 |
| 2025-07-07 | VRNA | Option Ex | 229,512 | .00 | 0 |
| 2025-06-11 | VRNA | Sale | 400,000 | 11.40 | 4,560,400 |
| 2025-05-27 | VRNA | Sale | 32,432 | 9.53 | 308,979 |
| 2025-05-29 | VRNA | Sale | 204,864 | 9.33 | 1,911,585 |
| 2025-05-28 | VRNA | Sale | 162,704 | 9.30 | 1,513,309 |
| 2025-05-01 | VRNA | Option Ex | 200,000 | .00 | 0 |
| 2025-05-01 | VRNA | Sale | 187,008 | 8.95 | 1,673,721 |
| 2025-05-02 | VRNA | Sale | 400,000 | 9.09 | 3,637,599 |
| 2025-04-29 | VRNA | Option Ex | 229,512 | .00 | 0 |
| 2025-04-29 | VRNA | Sale | 90,360 | 8.98 | 811,432 |
| 2024-12-05 | VRNA | Sale | 640,048 | 5.01 | 3,204,080 |
| 2024-12-04 | VRNA | Sale | 58,184 | 5.00 | 290,978 |
| 2024-12-06 | VRNA | Sale | 183,728 | 5.01 | 920,293 |
| 2024-11-27 | VRNA | Sale | 12,936 | 5.00 | 64,680 |
| 2024-11-29 | VRNA | Sale | 98,704 | 5.01 | 494,112 |
| 2024-12-02 | VRNA | Sale | 1,600 | 5.00 | 8,000 |
| 2024-11-26 | VRNA | Sale | 800 | 5.00 | 4,000 |
| 2024-11-25 | VRNA | Sale | 1,600 | 5.00 | 8,000 |
| 2024-11-01 | VRNA | Sale | 48,888 | 4.38 | 213,933 |
| 2024-11-04 | VRNA | Sale | 80,784 | 4.39 | 354,480 |
| 2024-10-25 | VRNA | Sale | 3,200 | 4.38 | 14,000 |
| 2024-10-24 | VRNA | Sale | 141,360 | 4.38 | 618,732 |
| 2024-10-18 | VRNA | Sale | 249,728 | 4.38 | 1,094,058 |
| 2024-10-21 | VRNA | Sale | 116,696 | 4.38 | 511,128 |
| 2024-10-22 | VRNA | Sale | 159,344 | 4.38 | 698,723 |
| 2024-09-11 | VRNA | Sale | 600,000 | 3.76 | 2,254,200 |
| 2024-08-13 | VRNA | Sale | 398,400 | 3.23 | 1,285,238 |
| 2024-08-12 | VRNA | Sale | 1,600 | 3.13 | 5,008 |
| 2023-08-03 | VRNA | Sale | 117,272 | 2.54 | 297,753 |
| 2023-08-04 | VRNA | Sale | 150,000 | 2.50 | 374,850 |
| 2023-08-07 | VRNA | Sale | 8,616 | 2.47 | 21,264 |
| 2023-08-01 | VRNA | Sale | 105,944 | 2.68 | 283,823 |
| 2023-08-02 | VRNA | Sale | 73,704 | 2.59 | 191,114 |
| 2023-05-01 | VRNA | Sale | 455,528 | 2.58 | 1,173,440 |
| 2023-02-01 | VRNA | Sale | 413,168 | 2.56 | 1,056,470 |
| 2022-08-09 | VRNA | Sale | 600,000 | 1.75 | 1,050,000 |
| 2022-08-01 | VRNA | Sale | 13,168 | .70 | 9,217 |
| 2022-05-03 | VRNA | Sale | 12,512 | .50 | 6,205 |
| 2022-02-02 | VRNA | Sale | 10,416 | .76 | 7,874 |
| 2021-11-02 | VRNA | Sale | 10,416 | .65 | 6,718 |
| 2021-08-02 | VRNA | Sale | 10,416 | .77 | 7,989 |
| 2021-05-03 | VRNA | Sale | 10,416 | .87 | 9,093 |
| 2021-03-01 | VRNA | Sale | 26,728 | 1.14 | 30,576 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-09-30 | DOVA | Sale | 775 | 28.00 | 21,700 |
| 2019-07-01 | DOVA | Sale | 1,545 | 14.17 | 21,892 |
| 2018-12-19 | DOVA | Buy | 2,500 | 6.28 | 15,700 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Hahn Mark W (Chief Financial Officer of Verona Pharma Plc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.